352 results on '"Turesson C"'
Search Results
2. POS0441 PREDICTORS OF GIANT CELL ARTERITIS IN PATIENTS WITH POLYMYALGIA RHEUMATICA IN SOUTHERN SWEDEN: A RETROSPECTIVE STUDY
3. AB0944 PREDICTORS AT DIAGNOSIS FOR INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH SPONDYLOARTHRITIS
4. POS0723 ANALYSES OF PLASMA METABOLIC PROTEINS REVEAL BIOMARKERS PREDICTIVE OF SUBSEQUENT DEVELOPMENT OF GIANT CELL ARTERITIS; A PROSPECTIVE STUDY
5. POS1080 THE IMPACT OF SYNOVITIS OF INDIVIDUAL FINGER JOINTS ON GRIP FORCE OVER THE FIRST FIVE YEARS IN EARLY RHEUMATOID ARTHRITIS
6. AB0414 FACTORS PREDICTING THE INITIATION OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS WITHIN THE FIRST THREE YEARS OF DIAGNOSIS
7. POS0617 SYNOVITIS OF THE FIRST METACARPOPHALANGEAL JOINT HAS A MAJOR IMPACT ON GRIP FORCE IN EARLY RHEUMATOID ARTHRITIS
8. POS0500 LEVELS OF IL-6 AND OTHER INFLAMMATORY PROTEINS IN EARLY RA PREDICT JOINT DAMAGE PROGRESSION OVER 5 YEARS
9. POS0559 COMPLIANCE WITH RECOMMENDATIONS OF LOW INTAKE OF RED MEAT AND HIGH FIBER INTAKE IS ASSOCIATED WITH A REDUCED RISK OF RHEUMATOID ARTHRITIS
10. Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis
11. A5.8 The use of cardiovascular risk module within the swedish rheumatology quality registry (SRQ) helps in daily clinical praxis
12. POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION
13. OP0122 COMPARATIVE EFFECTIVENESS OF JAKI VERSUS BDMARDS; A NATIONWIDE STUDY IN RA
14. POS0557 THE RELATION BETWEEN INVOLVEMENT OF INDIVIDUAL JOINTS OF THE UPPER EXTREMITY AND GRIP FORCE IN EARLY RHEUMATOID ARTHRITIS
15. OP0114 SHORT- AND LONGER-TERM RISKS FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS STARTING TREATMENT WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. A COLLABORATIVE OBSERVATIONAL HEAD-TO-HEAD STUDY ACROSS FIVE NORDIC RHEUMATOLOGY REGISTERS
16. OP0218 MORTALITY IN PATIENTS WITH PSORIATIC ARTHRITIS IN SWEDEN
17. POS0629 PREDICTORS OF CHANGE IN DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AFTER START OF TREATMENT WITH ABATACEPT
18. SAT0058 AGE DEPENDENT EFFECTS OF BODY MASS INDEX AND SMOKING ON THE RISK OF RHEUMATOID ARTHRITIS IN MEN – RESULTS FROM A NESTED CASE CONTROL STUDY
19. THU0303 TREATMENT OF GIANT CELL ARTERITIS WITH TOCILIZUMAB IN CLINICAL PRACTICE IN SWEDEN
20. Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis
21. Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort
22. Citrullination in extra-articular manifestations of rheumatoid arthritis
23. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis
24. Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis
25. Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis
26. Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis
27. Increased stiffness of the abdominal aorta in women with rheumatoid arthritis
28. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
29. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study
30. Epidemiology of extra-articular manifestations in rheumatoid arthritis
31. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years
32. Increased endothelial expression of HLA-DQ and interleukin 1α in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle
33. Lower extremity function in patients with early rheumatoid arthritis during the first five years, and relation to other disease parameters
34. Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis
35. DOES SEROPOSITIVITY INFLUENCE DIFFERENTIALLY DRUG DISCONTINUATION OF BIOLOGIC ANTIRHEUMATIC AGENTS WITH NON-ANTI-TNF MODE OF ACTION?
36. FRI0110 The impact of seropositivity on the effectiveness of abatacept versus tnf inhibitors in rheumatoid arthritis. real life data from several european registries (THE PAN-ABA STUDY)
37. FRI0245 Predictors for clinically diagnosed gout – 30 years follow-up in the malmÖ preventive project cohort, sweden
38. SAT0093 Male sex predicts a favourable outcome in seronegative early rheumatoid arthritis
39. FRI0073 Changes of bone mineral density over 10 years in patients with early rheumatoid arthritis
40. SAT0178 Predictors of drug survival of abatacept in rheumatoid arthritis – results from a large national quality register cohort study
41. FRI0653 Validity of polymyalgia rheumatica diagnoses, and classification criteria, in primary health care
42. FACTORS PREDICTING THE INITIATION OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS WITHIN THE FIRST THREE YEARS OF DIAGNOSIS.
43. THU0135 The course of lower extremity function in patients with early rheumatoid arthritis over the first five years
44. FRI0221 Does seropositivity influence differentially drug discontinuation of biologic antirheumatic agents with non-anti-tnf mode of action?
45. FRI0687 Body mass index, smoking, socioeconomic status and the risk of giant cell arteritis
46. FRI0686 Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis
47. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis
48. Body mass does not affect clinical outcomes of therapy with abatacept in rheumatoid arthritis (RA) patients. A pan-european analysis of RA registries
49. Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study
50. Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.